Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ALLO-501A by Allogene Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval
ALLO-501A is under clinical development by Allogene Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...
Data Insights
ALLO-501A by Allogene Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
ALLO-501A is under clinical development by Allogene Therapeutics and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...